125 related articles for article (PubMed ID: 15462490)
1. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus.
Tam LS; Li EK; Wong CK; Lam CW; Szeto CC
Lupus; 2004; 13(8):601-4. PubMed ID: 15462490
[TBL] [Abstract][Full Text] [Related]
2. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study.
Remer CF; Weisman MH; Wallace DJ
Lupus; 2001; 10(7):480-3. PubMed ID: 11480845
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
[TBL] [Abstract][Full Text] [Related]
4. Analysis of changes in joint function and peripheral blood mononuclear cells in patients with systemic lupus erythematosus and intervention effects of different drugs.
Zhou QS; Hu J; Hu H
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(19):4423-4430. PubMed ID: 29077150
[TBL] [Abstract][Full Text] [Related]
5. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial.
Chang DM; Lan JL; Lin HY; Luo SF
Arthritis Rheum; 2002 Nov; 46(11):2924-7. PubMed ID: 12428233
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.
Bengtsson AA; Sturfelt G; Lood C; Rönnblom L; van Vollenhoven RF; Axelsson B; Sparre B; Tuvesson H; Ohman MW; Leanderson T
Arthritis Rheum; 2012 May; 64(5):1579-88. PubMed ID: 22131101
[TBL] [Abstract][Full Text] [Related]
7. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study.
Vieira CS; Pereira FV; de Sá MF; Paulo LJ; Martins WP; Ferriani RA
Maturitas; 2009 Mar; 62(3):311-6. PubMed ID: 19193505
[TBL] [Abstract][Full Text] [Related]
8. Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial.
Mok CC; Ying SK; Ma KM; Wong CK
Lupus; 2013 Dec; 22(14):1470-8. PubMed ID: 24113197
[TBL] [Abstract][Full Text] [Related]
9. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis.
Cheng LE; Amoura Z; Cheah B; Hiepe F; Sullivan BA; Zhou L; Arnold GE; Tsuji WH; Merrill JT; Chung JB
Arthritis Rheumatol; 2018 Jul; 70(7):1071-1076. PubMed ID: 29513931
[TBL] [Abstract][Full Text] [Related]
10. Leflunomide: friend or foe for systemic lupus erythematosus?
Wu GC; Xu XD; Huang Q; Wu H
Rheumatol Int; 2013 Feb; 33(2):273-6. PubMed ID: 22961090
[TBL] [Abstract][Full Text] [Related]
11. Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement.
Yahya F; Jasmin R; Ng CT; Cheah TE; Sockalingam S
Int J Rheum Dis; 2013 Dec; 16(6):724-30. PubMed ID: 24119227
[TBL] [Abstract][Full Text] [Related]
12. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
Petri MA; Lahita RG; Van Vollenhoven RF; Merrill JT; Schiff M; Ginzler EM; Strand V; Kunz A; Gorelick KJ; Schwartz KE;
Arthritis Rheum; 2002 Jul; 46(7):1820-9. PubMed ID: 12124866
[TBL] [Abstract][Full Text] [Related]
13. Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study.
Alvarez-Nemegyei J; Cobarrubias-Cobos A; Escalante-Triay F; Sosa-Muñoz J; Miranda JM; Jara LJ
Lupus; 1998; 7(6):414-9. PubMed ID: 9736326
[TBL] [Abstract][Full Text] [Related]
14. [Leflunomide in systemic lupus erythematosus].
Kessel A; Toubi E
Harefuah; 2002 Apr; 141(4):355-7, 409. PubMed ID: 12017890
[TBL] [Abstract][Full Text] [Related]
15. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
Tseng CE; Buyon JP; Kim M; Belmont HM; Mackay M; Diamond B; Marder G; Rosenthal P; Haines K; Ilie V; Abramson SB
Arthritis Rheum; 2006 Nov; 54(11):3623-32. PubMed ID: 17075807
[TBL] [Abstract][Full Text] [Related]
16. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
Petri MA; Mease PJ; Merrill JT; Lahita RG; Iannini MJ; Yocum DE; Ginzler EM; Katz RS; Gluck OS; Genovese MC; Van Vollenhoven R; Kalunian KC; Manzi S; Greenwald MW; Buyon JP; Olsen NJ; Schiff MH; Kavanaugh AF; Caldwell JR; Ramsey-Goldman R; St Clair EW; Goldman AL; Egan RM; Polisson RP; Moder KG; Rothfield NF; Spencer RT; Hobbs K; Fessler BJ; Calabrese LH; Moreland LW; Cohen SB; Quarles BJ; Strand V; Gurwith M; Schwartz KE
Arthritis Rheum; 2004 Sep; 50(9):2858-68. PubMed ID: 15452837
[TBL] [Abstract][Full Text] [Related]
17. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
[TBL] [Abstract][Full Text] [Related]
18. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
Kalunian KC; Davis JC; Merrill JT; Totoritis MC; Wofsy D;
Arthritis Rheum; 2002 Dec; 46(12):3251-8. PubMed ID: 12483729
[TBL] [Abstract][Full Text] [Related]
19. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
Furie RA; Leon G; Thomas M; Petri MA; Chu AD; Hislop C; Martin RS; Scheinberg MA;
Ann Rheum Dis; 2015 Sep; 74(9):1667-75. PubMed ID: 24748629
[TBL] [Abstract][Full Text] [Related]
20. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
